Promising Potential of aTyr Pharma’s ATYR2810 in Glioblastoma Treatment: Analyst Recommends Buy

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains the same with $35.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the potential of aTyr Pharma’s ATYR2810 in treating aggressive cancer models. The preclinical data presented at AACR ’25 demonstrated that ATYR2810, a human monoclonal antibody, shows promising anti-tumor activity, particularly in glioblastoma multiforme (GBM), a challenging form of brain cancer. This is significant as ATYR2810 targets the NRP2/VEGF-C signaling axis, which is associated with tumor growth and resistance to current therapies.
Furthermore, the findings suggest that ATYR2810 can enhance anti-tumor immunity and improve overall survival rates when used alone or in combination with anti-PD-1 therapies. This dual approach of using ATYR2810 as a single agent or alongside other therapies could potentially reverse the immunosuppressive environment created by myeloid-derived suppressor cells in GBM. The early results are encouraging and indicate a promising clinical and regulatory path forward, reducing the risk and increasing the likelihood of success in future human studies.

Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Actinium Pharmaceuticals. According to TipRanks, Pantginis has an average return of -19.8% and a 22.78% success rate on recommended stocks.